SEARCH
ENGLISH
PDC drugs, peptide drug conjugate complex (Peptide Drug Conjugate), is to couple targeted peptides with drug molecules to enhance the targeting of drugs, concentrate the drugs on the target tissues, and reduce their relative concentration in other tissues. Improve effectiveness and reduce adverse reactions.
Drug molecules in PDC drugs are divided into chemical drugs and non-chemical drugs. Tumor targeting peptide conjugate drugs generally use cytotoxic drugs, such as paclitaxel, camptothecin, doxorubicin, and chlorambucil. The cytotoxic load of non-chemical drugs is commonly used in TNF, small interfering RNA (siRNA), and antisense oligonucleotides (AONs).
PDC drugs, peptide drug conjugate complex (Peptide Drug Conjugate), is to couple targeted peptides and drug molecules to enhance the targeting of drugs, concentrate the drugs on the target tissues, and reduce their relative concentration in other tissues. Improve effectiveness and reduce adverse reactions.
Drug molecules in PDC drugs are divided into chemical drugs and non-chemical drugs.
Tumor targeting peptide-conjugated drugs generally use cytotoxic drugs, such as paclitaxel, camptothecin, doxorubicin, and chlorambucil.
The cytotoxic loads of non-chemical drugs are often TNF, interfering small RNA (siRNA), and antisense oligonucleotides (AONs).
PDC drugs consist of three parts: a targeting peptide that specifically recognizes the receptor associated with the tumor cell, drug molecules that kill the tumor cell, and a linker that connects the drug molecule to the targeting peptide.
Drug molecules in PDC drugs are divided into chemical drugs and non-chemical drugs. Tumor targeting peptide conjugate drugs generally use cytotoxic drugs, such as paclitaxel, camptothecin, doxorubicin, and chlorambucil. The cytotoxic load of non-chemical drugs is commonly used in TNF, small interfering RNA (siRNA) and antisense oligonucleotides (AONs), etc.
PDC drugs are a conjugation between targeted peptides and drug molecules, which can enhance the target accuracy.
Peptides as carriers have high transport efficiency, low toxicity, no significant limitation on the size of all substances, and no association with inflammatory reactions. It can also effectively control the amount of material entering the cell and is therefore widely used in the field of drug transportation.
PDC drugs are considered one of the latest generations of target-specific anticancer drugs. Compared with ADC drugs, PDC drugs have the following advantages: a lower molecular weight (generally less than 3 kD), a higher loading capacity, lower immunogenicity, and lower production costs.
English 
